Phase III Biosimilar Clinical Trial & Infringement Threat Does Not Create Justiciable Case or Controversy: Biosimilars will Require the Patent Dance
‘Phase III Biosimilar Clinical Trial & Infringement Threat Does Not Create Justiciable Case or Controversy: Biosimilars Will Require the Patent Dance,’ by Peter Paredes, Lexology, December 15 2014.
Click here to access the article.